dorfmanmaster

Gilead in tested channel

Largo
NASDAQ:GILD   Gilead Sciences, Inc.
GILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir.

Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel, meaning the Risk-Reward-Ratio is at a good stance.

A close below the 50sma would change the sentiment, and remove us from the channel.

Exención de responsabilidad

La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.